Aflibercept monotherapy or bevacizumab first for diabetic macular edema
Purpose: Clinical outcome and switch patterns with bevacizumab first treatment strategy for patients with newly diagnosed neovascular age-related macular degeneration (nAMD). Methods: Retrospective observational study of the number of intravitreal injections of bevacizumab and treatment switch in pa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=14;spage=260;epage=264;aulast=Hostovsky |
| _version_ | 1797246483376898048 |
|---|---|
| author | Avner Hostovsky Iris Moroz Gabriel Katz |
| author_facet | Avner Hostovsky Iris Moroz Gabriel Katz |
| author_sort | Avner Hostovsky |
| collection | DOAJ |
| description | Purpose: Clinical outcome and switch patterns with bevacizumab first treatment strategy for patients with newly diagnosed neovascular age-related macular degeneration (nAMD). Methods: Retrospective observational study of the number of intravitreal injections of bevacizumab and treatment switch in patients who started intravitreal bevacizumab injections between January 1, 2016 and December 30, 2018. Results: From January 1 2016 to December 31 2018, 608 eyes of 565 patients started intravitreal injections of bevacizumab for a new diagnosis of nAMD. Average visual acuity (VA) at presentation was 0.60 logarithm of the minimum angle of resolution (logMAR), which improved to 0.47 after six injections (P < 0.001) and decreased to 0.63 at the last follow-up (P = 0.543). Switch of treatment was recommended for 190 eyes (31.3%), and of them, 91 patients (15%) were switched during the first 6 months and defined as primary failure of bevacizumab. The switch of treatment resulted in a statistically significant improvement in VA in the first 6 months after the switch. The gain in VA was not sustainable over time. Conclusion: Bevacizumab first treatment strategy produced results that were comparable to previous real-world outcomes publications of ranibizumab and aflibercept treatment with low rates of failure of bevacizumab treatment. Treatment switch to second-line treatment yielded a significant VA improvement, mainly in patients with primary bevacizumab failure. |
| first_indexed | 2024-04-24T19:43:31Z |
| format | Article |
| id | doaj.art-d9ae7ad4e2ff41ada582f8d71e15d951 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-04-24T19:43:31Z |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-d9ae7ad4e2ff41ada582f8d71e15d9512024-03-25T10:29:00ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892024-01-01721426026410.4103/IJO.IJO_2107_23Aflibercept monotherapy or bevacizumab first for diabetic macular edemaAvner HostovskyIris MorozGabriel KatzPurpose: Clinical outcome and switch patterns with bevacizumab first treatment strategy for patients with newly diagnosed neovascular age-related macular degeneration (nAMD). Methods: Retrospective observational study of the number of intravitreal injections of bevacizumab and treatment switch in patients who started intravitreal bevacizumab injections between January 1, 2016 and December 30, 2018. Results: From January 1 2016 to December 31 2018, 608 eyes of 565 patients started intravitreal injections of bevacizumab for a new diagnosis of nAMD. Average visual acuity (VA) at presentation was 0.60 logarithm of the minimum angle of resolution (logMAR), which improved to 0.47 after six injections (P < 0.001) and decreased to 0.63 at the last follow-up (P = 0.543). Switch of treatment was recommended for 190 eyes (31.3%), and of them, 91 patients (15%) were switched during the first 6 months and defined as primary failure of bevacizumab. The switch of treatment resulted in a statistically significant improvement in VA in the first 6 months after the switch. The gain in VA was not sustainable over time. Conclusion: Bevacizumab first treatment strategy produced results that were comparable to previous real-world outcomes publications of ranibizumab and aflibercept treatment with low rates of failure of bevacizumab treatment. Treatment switch to second-line treatment yielded a significant VA improvement, mainly in patients with primary bevacizumab failure.http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=14;spage=260;epage=264;aulast=Hostovskyafliberceptbevacizumabintravitreal injectionranibizumabswitch |
| spellingShingle | Avner Hostovsky Iris Moroz Gabriel Katz Aflibercept monotherapy or bevacizumab first for diabetic macular edema Indian Journal of Ophthalmology aflibercept bevacizumab intravitreal injection ranibizumab switch |
| title | Aflibercept monotherapy or bevacizumab first for diabetic macular edema |
| title_full | Aflibercept monotherapy or bevacizumab first for diabetic macular edema |
| title_fullStr | Aflibercept monotherapy or bevacizumab first for diabetic macular edema |
| title_full_unstemmed | Aflibercept monotherapy or bevacizumab first for diabetic macular edema |
| title_short | Aflibercept monotherapy or bevacizumab first for diabetic macular edema |
| title_sort | aflibercept monotherapy or bevacizumab first for diabetic macular edema |
| topic | aflibercept bevacizumab intravitreal injection ranibizumab switch |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=14;spage=260;epage=264;aulast=Hostovsky |
| work_keys_str_mv | AT avnerhostovsky afliberceptmonotherapyorbevacizumabfirstfordiabeticmacularedema AT irismoroz afliberceptmonotherapyorbevacizumabfirstfordiabeticmacularedema AT gabrielkatz afliberceptmonotherapyorbevacizumabfirstfordiabeticmacularedema |